Predicted protein targets (top 13)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | LMNA | P02545 | 1/20 | 0.59 |
| ▸ | SLC1A3 | P43003 | 6/20 | 0.46 |
| ▸ | SLC1A2 | P43004 | 6/20 | 0.46 |
| ▸ | SLC1A1 | P43005 | 6/20 | 0.46 |
| ▸ | PARP15 | Q460N3 | 3/20 | 0.39 |
| ▸ | PARP10 | Q53GL7 | 3/20 | 0.39 |
| ▸ | THRA | P10827 | 2/20 | 0.38 |
| ▸ | THRB | P10828 | 2/20 | 0.38 |
| ▸ | TP53 | P04637 | 1/20 | 0.36 |
| ▸ | CYP3A4 | P08684 | 1/20 | 0.36 |
| ▸ | ALOX5 | P09917 | 1/20 | 0.35 |
| ▸ | CYP2D6 | P10635 | 1/20 | 0.35 |
| ▸ | PARP2 | Q9UGN5 | 1/20 | 0.35 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL4631096 | 0.98 | LMNA (0.62) | LMNASLC1A3SLC1A2SLC1A1PARP15 | |
| SCHEMBL1864716 | 0.98 | LMNA (0.62) | LMNASLC1A3SLC1A2SLC1A1PARP15 | |
| Hydrochloric Acid SCHEMBL11848398 | 0.95 | LMNA (0.60) | LMNASLC1A3SLC1A2SLC1A1PARP15 | |
| SCHEMBL8393529 | 0.95 | — | — | |
| SCHEMBL1444507 | 0.90 | — | — | |
| SCHEMBL1672623 | 0.82 | LMNA (0.55) | LMNASLC1A3SLC1A2SLC1A1PARP15 | |
| SCHEMBL1472866 | 0.82 | LMNA (0.43) | LMNASLC1A3SLC1A2SLC1A1PARP15 | |
| SCHEMBL3744195 | 0.82 | LMNA (0.43) | LMNASLC1A3SLC1A2SLC1A1PARP15 | |
| SCHEMBL4892711 | 0.81 | LMNA (0.41) | LMNASLC1A3SLC1A2SLC1A1PARP15 | |
| SCHEMBL276585 | 0.80 | LMNA (0.46) | LMNASLC1A3SLC1A2SLC1A1PARP15 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 35 patents — showing the first 20. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| CN-111727185-A | Substituted N-heterocyclyl-and N-heteroaryltetrahydropyrimidines and their salts and their use as herbicidal active substances | 拜耳公司 | 2020-09-29 | — | — | CN | claimed |
| US-20150322094-A1 | USE OF SUBSTITUTED 2,3-DIHYDRO-1-BENZOFURAN-4-CARBOXYLIC ACIDS OR SALTS THEREOF AS ACTIVE SUBSTANCES AGAINST ABIOTIC PLANT STRESS | BAYER CROPSCIENCE AG (DE) | 2015-11-12 | — | — | US | claimed |
| US-20240150359-A1 | COMPOUNDS AND METHODS FOR TREATMENT OF VIRAL INFECTIONS | GILEAD SCIENCES, INC. | 2024-05-09 | — | — | US | disclosed |
| EP-4320128-A1 | COMPOUNDS AND METHODS FOR TREATMENT OF VIRAL INFECTIONS | GILEAD SCIENCES, INC. (US) | 2024-02-14 | — | — | EP | disclosed |
| US-11851438-B2 | 1′-cyano nucleoside analogs and methods for treatment of viral infections | GILEAD SCIENCES, INC. (US) | 2023-12-26 | — | — | US | disclosed |
| US-11845755-B2 | Compounds and methods for treatment of viral infections | GILEAD SCIENCES, INC. (US) | 2023-12-19 | — | — | US | disclosed |
| US-20230382940-A1 | ANTIVIRAL COMPOUNDS AND METHODS OF MAKING AND USING THE SAME | GILEAD SCIENCES, INC. | 2023-11-30 | — | — | US | disclosed |
| US-11780844-B2 | Compounds and methods for treatment of viral infections | GILEAD SCIENCES, INC. (US) | 2023-10-10 | — | — | US | disclosed |
| US-20230295172-A1 | COMPOUNDS AND METHODS FOR TREATMENT OF VIRAL INFECTIONS | GILEAD SCIENCES, INC. | 2023-09-21 | — | — | US | disclosed |
| US-20230279014-A1 | COMPOUNDS AND METHODS FOR TREATMENT OF VIRAL INFECTIONS | GILEAD SCIENCES, INC. | 2023-09-07 | — | — | US | disclosed |
| US-20230279015-A1 | COMPOUNDS AND METHODS FOR TREATMENT OF VIRAL INFECTIONS | GILEAD SCIENCES, INC. | 2023-09-07 | — | — | US | disclosed |
| US-20030134830-A1 | Bioavailable prodrugs of androgenic steroids and related method | BIOTEST LABORATORIES, LLC | 2003-07-17 | — | — | US | disclosed |
| US-5864043-A | CARDIOVASCULAR DISORDERS AND ANGIOTENSIN ANTAGONIST | KARL THOMAE GMBH (DE) | 1999-01-26 | — | — | US | disclosed |
| EP-0804416-A1 | HETEROCYCLIC COMPOUNDS, USEFUL AS ALLOSTERIC EFFECTORS AT MUSCARINIC RECEPTORS | SANKYO COMPANY LIMITED (JP) | 1997-11-05 | — | — | EP | disclosed |
| US-5637731-A | CHOLINERGIC AGENTS | AMERICAN HOME PRODUCTS CORPORATION (US) | 1997-06-10 | — | — | US | disclosed |
| US-5550257-A | TREATING CENTRAL CHOLINERGIC DYSFUNCTION | AMERICAN CYANAMID COMPANY (US) | 1996-08-27 | — | — | US | disclosed |
| US-5541229-A | ANGIOITENSIN II ANTAGONIST AS HYPOTENSIVE AGENTS, ANTIISCHEMIC AGENTS AND CARDIOVASCULAR DISORDERS | DR. KARL THOMAE GMBH (DE) | 1996-07-30 | — | — | US | disclosed |
| WO-1996003377-A1 | HETEROCYCLIC COMPOUNDS, USEFUL AS ALLOSTERIC EFFECTORS AT MUSCARINIC RECEPTORS | SANKYO COMPANY, LIMITED (JP) | 1996-02-08 | — | — | WO | disclosed |
| EP-0529022-B1 | NEW LEUKOTRIENE B 4? DERIVATIVES, METHOD FOR PREPARING THEM AND THEIR USE AS DRUGS | SCHERING AG (DE) | 1995-09-27 | — | — | EP | disclosed |
| WO-1992016504-A1 | NEW LEUKOTRIENE B4 DERIVATIVES, METHOD FOR PREPARING THEM AND THEIR USE AS DRUGS | SCHERING AKTIENGESELLSCHAFT BERLIN UND BERGKAMEN (DE) | 1992-10-01 | — | — | WO | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (9 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-11780844-B2 | Compounds and methods for treatment of viral infections | HAVCR2, EIF2AK2, OAT | LMNA 1800/4885SLC1A3 4515/4885SLC1A2 4542/4885 |
| US-20240150359-A1 | COMPOUNDS AND METHODS FOR TREATMENT OF VIRAL INFECTIONS | HAVCR2, EIF2AK2, OAT | LMNA 1800/4885SLC1A3 4515/4885SLC1A2 4542/4885 |
| US-20230279015-A1 | COMPOUNDS AND METHODS FOR TREATMENT OF VIRAL INFECTIONS | HAVCR2, EIF2AK2, OAT | LMNA 1800/4885SLC1A3 4515/4885SLC1A2 4542/4885 |
| US-20230382940-A1 | ANTIVIRAL COMPOUNDS AND METHODS OF MAKING AND USING THE SAME | EIF2AK2, MAVS, ZC3HAV1 | LMNA 2192/4885SLC1A3 4329/4885SLC1A2 4657/4885 |
| US-20150322094-A1 | USE OF SUBSTITUTED 2,3-DIHYDRO-1-BENZOFURAN-4-CARBOXYLIC ACIDS OR SALTS THEREOF AS ACTIVE SUBSTANCES AGAINST ABIOTIC PLANT STRESS | CAT, HSF1, HPD | LMNA 4642/4885SLC1A3 2422/4885SLC1A2 1302/4885 |
| US-20230279014-A1 | COMPOUNDS AND METHODS FOR TREATMENT OF VIRAL INFECTIONS | HAVCR2, EIF2AK2, OAT | LMNA 1800/4885SLC1A3 4515/4885SLC1A2 4542/4885 |
| US-11851438-B2 | 1′-cyano nucleoside analogs and methods for treatment of viral infections | TYMP, PNP, SAMHD1 | LMNA 509/4885SLC1A3 1627/4885SLC1A2 1824/4885 |
| US-11845755-B2 | Compounds and methods for treatment of viral infections | HAVCR2, EIF2AK2, OAT | LMNA 1800/4885SLC1A3 4515/4885SLC1A2 4542/4885 |
| US-20230295172-A1 | COMPOUNDS AND METHODS FOR TREATMENT OF VIRAL INFECTIONS | HAVCR2, EIF2AK2, OAT | LMNA 1800/4885SLC1A3 4515/4885SLC1A2 4542/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.